Settle®
An immunotherapeutic for treating endometritis in mares.

Settle is a USDA-approved immunotherapeutic that is recommended as an aid in the treatment of equine endometritis caused by *Streptococcus zooepidemicus*. The product is approved for both intravenous and intrauterine administration.

Endometritis is an important disease with significant economic impact to the horse industry. It is estimated that this non-life threatening disease affects up to 43% of broodmares worldwide. Settle is the world’s first and only immunotherapeutic licensed to treat equine endometritis.

Studies have shown that a single dose of Settle can help resolve a broodmare’s uterine infection and the damaging inflammation it causes.

Prepare your client’s mares for effective breeding.
Settle, mycobacterium cell wall fraction (MCWF) immunostimulant, is recommended as an aid in the treatment of equine endometritis caused by *Streptococcus zooepidemicus*. The product is approved for both intravenous and intrauterine administration.

**Endometritis in the Broodmare**

Endometritis in mares is an important disease that has significant economic impact on the horse industry. Mares can be classified as resistant or susceptible according to their ability to clear uterine fluid within 48 hours of breeding or bacterial inoculation. These mares are usually older or barren with a history of endometritis. The most commonly used treatment for endometritis is antibiotics.

**The Pathogenesis of Endometritis**

Involution and clearing of the mare’s uterus is normally accomplished by the foal heat at approximately one to two weeks after parturition. Although mares can be bred at this heat, it is more common to breed them at the next heat, approximately one month after foaling. At breeding, the deposition of semen, bacteria and debris into the uterus induces a self-limiting endometritis that is normally cleared within 48 hours. Mares that are susceptible to persistent post-breeding endometritis (PPBE) have an impaired uterine immune-defense and clearance mechanisms that does not allow them to resolve this inflammation prior to the embryo entering the uterus and attempting implantation. Mares with PPBE have an increased rate of embryonic loss and a lower overall pregnancy rate than those without the condition. To enhance conception rates, mares at high risk need early diagnosis, optimal breeding management and appropriate treatment.

**When to use Settle**

Settle is recommended as an aid in the treatment of equine endometritis caused by *Streptococcus zooepidemicus*. It is administered as a 1.5 mL dose by intrauterine instillation with a sterile catheter or by intravenous injection into the jugular vein during the early estrus period. Treatment may be repeated at subsequent natural or induced estrus periods.

Settle has been used successfully:

- At the diagnosis of uterine infection and while awaiting culture or sensitivity test results
- The day after foaling (or at the first sign of estrus) in known endometritis-susceptible mares or those mares recognized as difficult breeders
- At time of retained placenta removal (and/or at the first heat of mares with history of retained placenta or delayed expulsion)
- The day after foaling (or at first natural heat) in mares with poor reproductive tract conformation
- The day after foaling to ensure earlier uterine involution and health
- The day after foaling to facilitate earlier breeding when mares are late in the season or to increase conception at the foal heat
- At diagnosis of uterine inflammation or poor involution
- At the time of natural breeding or artificial insemination
- Immediately prior to shipping mares for breeding to expensive stallions

If you would like additional information, articles, or research data about Settle, please e-mail us at info@novavive.ca.